hupo2017@conferencepartners.ie

Yu-Ju Chen

Yu-Ju Chen

Research Fellow and Director
Institute of Chemistry
Academia Sinica, Taiwan

Talk Title: Pathway to Next Generation Precision Medicine:
Prospective from Taiwan Cancer Moonshot to Address Unmet Clinical Needs

Bio

Dr. Chen obtained her Ph.D. in physical chemistry from Iowa State University (1997) and postdoctoral training at the Ames Laboratory, USA [1997] and National Tsing Hua University, Taiwan [1999]. She also currently holds con-current adjunct professorships at few universities.
Being one of the pioneering proteomic groups in Taiwan, Dr. Yu-Ju Chen has devoted her efforts to develop mass spectrometry-based methodologies for membrane proteome and post-translational modificom and their application to delineate the proteome network in biology and diseases. She has serve as EC Member of HUPO, Council Member and current VP of AOHUPO. She has been the President for both “Taiwan Proteomics Society” and “Taiwan Society for Mass Spectrometry”. She is acting as Senior Editor of “Proteomics” and editorial board member of the EJMS and J. Proteom. Res. Dr. Chen has published more than 140 articles including Nat. Commun., Cancer Cell, Mol. & Cell. Proteom., Anal. Chem., J. Am. Chem. Soc., and Proc. Natl. Acad. Sci., and 5 patents.

Abstract:

The different genetic background and environmental factors contribute to unique features of cancers in diversity of population (e.g. Taiwan/Asian), awaiting full delineation of genomic-to-proteomic network to identify the fundamental drivers of cancer and the individual responsiveness and failure to therapy. With the aim of accelerating the progress toward prevention, control and treatment for cancer, Taiwan joined the global effort of Cancer Moonshot initiated by the US to apply proteogenomics as a precision approach to delineate the connection of genomic abnormalities and protein alteration in individual cancer patient’s tissues. Subsequently, the Cancer Proteogenomics Moonshot project was included by Board of Science and Technology in Taiwan as an action plan under the “Biomedical Industrial Innovation Program”, a newly launched roadmap in late 2016 to build Taiwan as Asia-Pacific hub for biomedical research and development. In this talk, I will present how this project stimulates academia-government-industry collaboration and challenges as well as our expectation to map the pathway for next generation precision medicine to address unmet clinical needs in Taiwan/Asia.